Aspen Repurchases 6.3% of Issued Shares
The drugmaker bought back 28.3 million shares and agreed to sell European rights to its Ovestin brand for €197 million.
Updated on Nov. 10, 2026 in Corporate Finance

Aspen Pharmacare repurchased 28.3 million shares, representing 6.3% of its issued share capital. The company also agreed to sell European commercialisation rights for Ovestin to Ennogen Healthcare International for €197 million.
Why it matters
The buyback follows the group's efforts to reduce debt and simplify its operations. For South African investors, the transactions show how the Durban-headquartered drugmaker is reshaping its portfolio as it expands into weight-loss medicines.
Aspen bought back 14.99 million shares for R2.43 billion between 2 and 3 November 2026 at an average price of R162.01, and 13.33 million shares for R1.98 billion between May and August 2026. The company has authority to repurchase a further 60.9 million shares, equal to 13.7% of capital, leaving open how much of that authority will be used.
The players
Aspen Pharmacare
Durban-headquartered pharmaceutical manufacturer that is one of South Africa's largest listed drugmakers and a major producer of generic medicines.
Ennogen Healthcare International
Buyer of the European commercialisation rights for Ovestin, a hormone therapy brand, under the agreement announced alongside the buyback.
The details
Aspen was authorised by shareholders in December 2025 to undertake the buyback. The Ovestin transaction includes European commercialisation rights and related intellectual property, valued at €197 million or R3.7 billion, excluding inventory worth around €4 million. Aspen will continue to manufacture and supply Ovestin's active pharmaceutical ingredient and cream formulation under agreements lasting at least 10 years.
Timeline
December 2025: Shareholders approved general buyback authority.
May to August 2026: Aspen repurchased 13.33 million shares for R1.98 billion.
2 to 3 November 2026: Aspen repurchased 14.99 million shares for R2.43 billion.
5 November 2026: Aspen announced the buyback details via SENS.
Market Dynamics
The buyback extends a repurchase run that began in May 2026 and has now reached roughly R4.41 billion in total value. Aspen's asset sale and share purchases together signal a capital strategy focused on reducing debt and reshaping the group around its growth areas, including its entry into the weight-loss medicine market.
Shareholders who remain invested benefit from a smaller pool of shares, as buybacks reduce the number of shares in circulation. Investors can track the remaining 60.9 million shares of repurchase authority through Aspen's SENS announcements to gauge whether further buybacks are likely.
The takeaway
Aspen's buyback and Ovestin sale show a drugmaker trimming its capital base while funding its move into weight-loss medicines. Investors watching the company should follow whether the remaining repurchase authority is used and how the Ovestin proceeds are applied.
Further reading
For more on how listed companies manage their balance sheets, see Corporate Finance coverage on Wisevoter.






